Tech Company Financing Transactions
Epiterna Funding Round
On 8/1/2023, Epiterna raised $11 million in financing from Prima Materia.
Transaction Overview
Company Name
Announced On
8/1/2023
Transaction Type
Venture Equity
Amount
$10,950,000
Round
Undisclosed
Investors
Prima Materia (Lead Investor)
Proceeds Purpose
Epiterna is developing products using drugs and chemical compounds which have already been approved to treat humans, dogs and cats for specific diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Route de la Corniche 5A
Epalinges, 1066
CH
Epalinges, 1066
CH
Phone
Undisclosed
Website
Email Address
Overview
Ageing is one of the greatest challenges of our time. As the major risk factor for diseases and functional decline, it is at the root of the most devastating health problems we face. Science has demonstrated that we can slow the ageing process and extend the lives of animals in the laboratory. EPITERNA was founded to translate these discoveries into longer, healthier and happier lives -- for companion dogs and cats, and for people. Our team develops affordable products that can safely slow the ageing process to prevent age-related disease, delay functional decline, and extend life.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alejandro Ocampo
Co-Founder
Kevin Perez
Browse more venture capital transactions:
Prev: 8/1/2023: 1Bstories venture capital transaction
Next: 8/1/2023: Aulos Bioscience venture capital transaction
Share this article
About Database of VC Transactions
We document funding rounds that are announced publicly. All VC database entries reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs